Valeant Pharma (VRX) Reports Q1 Adjusted EBITDA of $861M
Tweet
Share
E-mail
Get Alerts VRX Hot Sheet
Price: $23.40 --0%
Financial Fact:
Net income per share attributable to Valeant: 0.39
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Net income per share attributable to Valeant: 0.39
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Valeant Pharma (NYSE: VRX) reported GAAP Q1 EPS of $1.79, versus $1.08 reported last year. Revenue for the quarter came in at $2.11 billion, versus $2.37 billion reported last year.
- Adjusted EBITDA (non-GAAP) of $861 Million
2017 Guidance
2017 Full Year Adjusted EBITDA (non-GAAP) in the range of $3.60 - $3.75 billion from $3.55 - $3.70 billion
For earnings history and earnings-related data on Valeant Pharma (VRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- Investing.com’s stocks of the week
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
